Syneos Health has promoted seasoned talent to lead creative expression and strategy in communications that drive positive health outcomes.
Posts
Burnham will be responsible for overseeing the partnership of brand and medical strategists on each of Greater Than One’s accounts, to build better healthcare experiences for customers.
“Kim makes so much sense for Coefficient Health, because we believe that people with diverse profiles help elevate the excellence of our work. With her extensive experience across therapeutic categories, creative disciplines, and unique audiences, Kim’s background is in exact alignment with that ethos,” said founding partner Dave Miller. “Bringing her onto the team will only help advance our ability to bring the most impactful, integrated creative solutions to our clients.”
Based in Tokyo, the new agency brings the storied FCB Health brand and it’s “never finished” spirit to the Japanese market – the world’s third largest pharmaceutical sector. The agency will harness and maximize the power of the global IPG Health network to continue delivering the best talent, capabilities, expertise, and customized solutions for clients in Japan.
The top pharmaceutical companies and brands in this year’s Outcomes Creativity Index elevated their messaging by breaking down barriers, debunking myths and giving patients a stronger voice.
Together, both companies will build scalable, purpose-built teams that partner across disciplines and geographies to accelerate customer performance.
The fast-growing global naming and branding firm hired Switzerland-based Dan Hunt as managing director, Europe.
Creative & broadcast talent from across U.S. and Canada continue to flock to Klick to create work that makes a difference and be part of large indie health agency’s renowned culture. The agency also announced Klick Brands, Studio K, and Klick Influence to elevate life sciences clients’ brands and content in quickly evolving marketplace.
The long-awaited digital transformation of life sciences has arrived. It went from a promise to a need.
It is vital that, from the beginning of a medicine’s development, a regulatory strategy is built into all activities so companies may optimize value, control costs and reduce risks – all while ensuring proper compliance. If any step is missed along the way, lifescience companies will encounter roadblocks in the form of delays on approval cycles and lack of proper data control, which can impact the long-term revenue for the medicine.
